Novel approaches for the discovery of pharmacogenetic biomarkers of chemotoxicity in patients with colorectal cancer.

Saved in:
Bibliographic Details
Title: Novel approaches for the discovery of pharmacogenetic biomarkers of chemotoxicity in patients with colorectal cancer.
Authors: Simoes AR; Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain., Carlés González S; Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain., Lopez-Doldan MDC; Oncological Pharmacy Unit, Complexo Hospitalario Universitario de Ourense, Ourense, Spain., Duran G; University Hospital of Santiago de Compostela Pharmacy Service, Santiago de Compostela, Spain., Fernández-Montes A; Medical Oncology Unit, Complexo Hospitalario Universitario de Ourense, Ourense, Spain., Fernandez MP; Oncological Pharmacy Unit, Complexo Hospitalario Universitario de Ourense, Ourense, Spain., Salgado Fernandez M; Medical Oncology Unit, Complexo Hospitalario Universitario de Ourense, Ourense, Spain., Garcia Mata J; Medical Oncology Unit, Complexo Hospitalario Universitario de Ourense, Ourense, Spain., Paez D; Hospital de la Santa Creu i Sant Pau, Medical Oncology Department, Barcelona, Spain.; Institut d'Investigacio Biomedica Sant Pau, Translational Medical Oncology Laboratory, Barcelona, Spain.; Center for Biomedical Research in Network on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain., Riera P; Institut d'Investigacio Biomedica Sant Pau, Translational Medical Oncology Laboratory, Barcelona, Spain.; Pharmacy Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.; Center for Biomedical Research in Network on Rare Diseases (CIBERER), Instituto de Salud Carlos III, Madrid, Spain., Guino E; Catalan Institute of Oncology, Oncology Data Analytics Program, Barcelona, Spain.; Bellvitge Institute for Biomedical Research, Colorectal Cancer Group; Molecular Mechanisms and Experimental Therapy in Oncology (ONCOBELL) Program, Barcelona, Spain.; Biomedical Research Center in Network of Epidemiology and Public Health, Consortium (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain., Lopez-Fernandez L; Hospital General Universitario Gregorio Marañón Servicio de Farmacia, Madrid, Spain.; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain., Garcia de Santiago B; Infanta Sofia University Hospital, Pharmacy Service, Madrid, Spain., López Aspiroz E; Infanta Sofia University Hospital, Pharmacy Service, Madrid, Spain.; Universidad Europea de Madrid, Faculty of Medicine, Health and Sports, Madrid, Spain., Rojas A; Tecnologico de Monterrey, School of Medicine and Health Sciences, Monterrey, Mexico., Castells A; Hospital Clínic Barcelona, Gastroenterology Unit, Barcelona, Spain.; Gastroenterology Department, Institut d' Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain., Castellvi-Bel S; Hospital Clínic Barcelona, Gastroenterology Unit, Barcelona, Spain.; Gastroenterology Department, Institut d' Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.; Hospital Clínic Barcelona, Gastroenterology Department, Barcelona, Spain., Ruiz Ponte C; Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain.; Galician Public Foundation for Genomic Medicine (FPGMX), Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain., Vymetalkova V; Department of Molecular Biology of Cancer, Charles University, Institute of Experimental Medicine of the Czech Academy of Sciences, Prague, Czech Republic., Carracedo A; Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain.; Galician Public Foundation for Genomic Medicine (FPGMX), Santiago de Compostela, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain.; Genomic Medicine Group, Universidade de Santiago de Compostela, Santiago de Compostela, Spain., Fernandez-Rozadilla C; Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain.; Galician Public Foundation for Genomic Medicine (FPGMX), Santiago de Compostela, Spain.; Genomic Medicine Group, Universidade de Santiago de Compostela, Santiago de Compostela, Spain.
Source: British journal of pharmacology [Br J Pharmacol] 2025 Nov; Vol. 182 (21), pp. 5340-5354. Date of Electronic Publication: 2025 Jul 07.
Publication Type: Journal Article
Journal Info: Publisher: Wiley Country of Publication: England NLM ID: 7502536 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5381 (Electronic) Linking ISSN: 00071188 NLM ISO Abbreviation: Br J Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5381
DOI:10.1111/bph.70051